SEC Form 4 · accession 0001562180-16-001768
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Patterson
Officer — EVP, Nat. Accts and Corp. Dev.
Period of report
Feb 21, 2016
Accepted (ET)
Feb 23, 2016 · 5:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 21, 2016 | F | 637 | $14.61 | D | 41,321 | D | |
| Common Stock | Feb 22, 2016 | F | 406 | $14.61 | D | 40,915 | D | |
| Common Stock | Feb 22, 2016 | A | 8,214 | $0.00 | A | 49,129 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option to BuyF1 | $14.61 | Feb 22, 2016 | A | 17,391 | A | — | Feb 22, 2026 | Common Stock | 17,391 | 17,391 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on February 22, 2017.